Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial - Jean-Michel Molina, Kathleen Squires, Paul E. Sax, Pedro Cahn, Sushma Kumar, Edwin DeJesus, Johan Lombaard, Debbie P. Hagins, Melanie A. Thompson, Ming-Tain Lai, Olayemi O. Osiyemi, David James Prelutsky, Anthony Rodgers, Moti N. Ramgopal, Anthony John Scarsella - Dissemin

Language
Login

Published in

Elsevier, The Lancet HIV, 1(7), p. e16-e26, 2020

DOI: 10.1016/s2352-3018(19)30336-4

Links

Tools

Export citation

Search in Google Scholar

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Journal article published in 2020 by Jean-Michel Molina, Kathleen Squires, Paul E. Sax, Pedro Cahn, Sushma Kumar, Edwin DeJesus, Johan Lombaard, Debbie P. Hagins, Melanie A. Thompson, Ming-Tain Lai, Olayemi O. Osiyemi, David James Prelutsky, Anthony Rodgers, Moti N. Ramgopal, Anthony John Scarsella and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO